標(biāo)題: Titlebook: Drugs for the Treatment of Parkinson’s Disease; Donald B. Calne (Head) Book 1989 Springer-Verlag Berlin Heidelberg 1989 Parkinson.adverse [打印本頁] 作者: charity 時(shí)間: 2025-3-21 18:23
書目名稱Drugs for the Treatment of Parkinson’s Disease影響因子(影響力)
書目名稱Drugs for the Treatment of Parkinson’s Disease影響因子(影響力)學(xué)科排名
書目名稱Drugs for the Treatment of Parkinson’s Disease網(wǎng)絡(luò)公開度
書目名稱Drugs for the Treatment of Parkinson’s Disease網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Drugs for the Treatment of Parkinson’s Disease被引頻次
書目名稱Drugs for the Treatment of Parkinson’s Disease被引頻次學(xué)科排名
書目名稱Drugs for the Treatment of Parkinson’s Disease年度引用
書目名稱Drugs for the Treatment of Parkinson’s Disease年度引用學(xué)科排名
書目名稱Drugs for the Treatment of Parkinson’s Disease讀者反饋
書目名稱Drugs for the Treatment of Parkinson’s Disease讀者反饋學(xué)科排名
作者: ineptitude 時(shí)間: 2025-3-21 23:43
Mohammad Ali Salahuddin,Ala Al-Fuqahavariety of other coincidental lesions elsewhere in the CNS. Unilateral parkinsonism is associated with predominant damage to the contralateral brain stem or substantia nigra (. and . 1893; . 1964; . and . 1973; . 1984), while only in exceptional cases of parkinsonism no morphological lesions of the 作者: 表示向前 時(shí)間: 2025-3-22 03:53
Routing in WSNs for Space Applicationve reviewed the literature on the afferents and efferents of the caudate/putamen (CP), globus pallidus (GP), and substantia nigra (SN), and on the neurotransmitters occurring in the various tracts (. et al. 1984). We present updates of those diagrams in the Appendix to this chapter, as well as new d作者: Parallel 時(shí)間: 2025-3-22 07:00 作者: TEN 時(shí)間: 2025-3-22 09:34
Reflections from Key Design Team Membersenough to warrant medical attention. Furthermore, the diagnosis is often missed in the early stages of the disease and the symptoms may be incorrectly attributed to a variety of other problems. Therefore, the variability in reported prevalence figures can be partly explained by differences in the me作者: 憤慨一下 時(shí)間: 2025-3-22 16:44 作者: 憤慨一下 時(shí)間: 2025-3-22 17:12 作者: 美麗的寫 時(shí)間: 2025-3-23 01:05
Neurophysiology of Basal Ganglia,r with greatly reduced frequency and speed, argue for defects in neuronal processes that need to be operational before the motor act begins. These are less easy to define and may comprise mechanisms such as volition, incentive, motivation, memory, arousal, intention, attention, reactivity, sensory d作者: 連累 時(shí)間: 2025-3-23 02:05 作者: 小畫像 時(shí)間: 2025-3-23 07:19
Biochemical Neuroanatomy of the Basal Ganglia,ve reviewed the literature on the afferents and efferents of the caudate/putamen (CP), globus pallidus (GP), and substantia nigra (SN), and on the neurotransmitters occurring in the various tracts (. et al. 1984). We present updates of those diagrams in the Appendix to this chapter, as well as new d作者: Kaleidoscope 時(shí)間: 2025-3-23 12:58
,The Neurochemical Basis of the Pharmacology of Parkinson’s Disease,e marketed preparation, or the impenetrability of the blood-brain barrier to DA. From the very wide variety of drugs and (tissue) preparations that have been proposed as potential remedies for PD, it can be concluded that the results of this century-long empirical approach to pharmacotherapy of PD w作者: RAGE 時(shí)間: 2025-3-23 16:23 作者: alcohol-abuse 時(shí)間: 2025-3-23 18:13 作者: Ceremony 時(shí)間: 2025-3-23 23:52 作者: 物質(zhì) 時(shí)間: 2025-3-24 02:34 作者: 鳴叫 時(shí)間: 2025-3-24 07:48
Kate J. Bowers,Shane D. Johnson of symptomatic therapy for neurodegenerative disease as effectively targeted for the essential pathophysiology as is LD against PD. In the last two decades, use of LD has become so pervasive that it is virtually impossible to study the natural history of PD without the intervening factor of LD therapy.作者: CON 時(shí)間: 2025-3-24 11:33
Benjamin Schwessinger,John P. Rathjenaranoia, insomnia, and an awakening effect. The dyskinesias were chorea, myoclonus, hemiballism (ipsilateral to the side of a prior thalamotomy), and dystonia. These adverse effects subsided with lowering of the dosage.作者: 評論者 時(shí)間: 2025-3-24 18:19
Benjamin Schwessinger,John P. Rathjeness of Parkinson’s disease. In this chapter, the clinical experience to date of the use of .-deprenyl in regard to its pharmacologic properties, indications for use, and effectiveness in the control of parkinsonism will be discussed.作者: rheumatology 時(shí)間: 2025-3-24 23:05 作者: Cardioplegia 時(shí)間: 2025-3-25 01:44 作者: 利用 時(shí)間: 2025-3-25 03:49 作者: 愛花花兒憤怒 時(shí)間: 2025-3-25 07:28
,Clinical Actions of ,-Deprenyl in Parkinson’s Disease,ess of Parkinson’s disease. In this chapter, the clinical experience to date of the use of .-deprenyl in regard to its pharmacologic properties, indications for use, and effectiveness in the control of parkinsonism will be discussed.作者: Angiogenesis 時(shí)間: 2025-3-25 14:02
Mohamed Riduan Abid,Driss Benhaddouand postsynaptic elements. Other neurotransmitter abnormalities, however, have been observed in this and other basal ganglia diseases. This chapter will focus on the normal distribution of neurotransmitter receptors in human basal ganglia and the receptor abnormalities observed in Parkinson’s disease.作者: Ergots 時(shí)間: 2025-3-25 17:32
Worship Spaces: 1001–2000 Seatsty of deficits (such as dementia), and experience with problematic adverse reactions (such as fluctuations in response). Besides making reliable sensitive assessment more important, complications such as dementia and fluctuations in response make the process of evaluation more difficult.作者: 序曲 時(shí)間: 2025-3-25 23:13
Benjamin Schwessinger,John P. Rathjenerature if not exposed to light. Lisuride hydrogen maleate is soluble in water or saline up to 1 mg/ml. Owing to its low effective dose, it is therefore the first dopamine agonist which can also be used on a parenteral basis (. et al. 1980).作者: Criteria 時(shí)間: 2025-3-26 03:58 作者: 分解 時(shí)間: 2025-3-26 06:30 作者: Malfunction 時(shí)間: 2025-3-26 09:53
,Lisuride Pharmacology and Treatment of Parkinson’s Disease,erature if not exposed to light. Lisuride hydrogen maleate is soluble in water or saline up to 1 mg/ml. Owing to its low effective dose, it is therefore the first dopamine agonist which can also be used on a parenteral basis (. et al. 1980).作者: 考博 時(shí)間: 2025-3-26 15:39
Developmental and Social Prevention, this chapter we will review anticholinergic and amantadine treatment of Parkinson’s disease, emphasizing the proposed mechanisms of action, what is known of the pharmacokinetics, the clinical effectiveness and side effects.作者: Infant 時(shí)間: 2025-3-26 16:49
,Anticholinergic Drugs and Amantadine in the Treatment of Parkinson’s Disease, this chapter we will review anticholinergic and amantadine treatment of Parkinson’s disease, emphasizing the proposed mechanisms of action, what is known of the pharmacokinetics, the clinical effectiveness and side effects.作者: 貪婪的人 時(shí)間: 2025-3-27 00:08 作者: 連接 時(shí)間: 2025-3-27 03:41 作者: 任意 時(shí)間: 2025-3-27 05:32
Introduction to Wireless Sensor Networksinical neuroscience in the last decade. Not only have these techniques revolutionized the clinical management of patients with neurological disorders, but in many situations they have advanced our understanding of the pathophysiology of diseases which affect the Brain.作者: 駭人 時(shí)間: 2025-3-27 09:41
Benjamin Schwessinger,John P. Rathjentain this response and become more symptomatic. Increasing disability is usually accompanied by dyskinesias and diurnal fluctuations in performance, predominantly “wearing-off” phenomena (. and . 1977; 1976). Occasionally, patients exhibit abrupt random fluctuations: “on-off” phenomena.作者: neoplasm 時(shí)間: 2025-3-27 16:04 作者: 靈敏 時(shí)間: 2025-3-27 17:58
Moussa Ayyash,Y. Alsbou,Mohamed Anan deficits in the basal ganglia would suggest at first sight a role of this brain structure in motor control. However, an absence of movement can have many causes. When discussing movement-related neuronal processes it is helpful to distinguish between the initiation and the execution of movements (.作者: rectocele 時(shí)間: 2025-3-28 00:40
Mohammad Ali Salahuddin,Ala Al-Fuqaharvous system (CNS), basically characterized by dysfunction of the dopaminergic nigrostriatal system. It may or, rarely, may not be associated with distinct anatomic damage to the melanin-containing neurons of the substantia nigra, changes to the neuronal cytoskeleton, including the Lewy bodies, and 作者: CANT 時(shí)間: 2025-3-28 04:41 作者: 迷住 時(shí)間: 2025-3-28 08:19
Mohamed Riduan Abid,Driss Benhaddou the function of specific neuronal pathways in health and disease. In Parkinson’s disease, the emphasis has been on the study of dopamine presynaptic and postsynaptic elements. Other neurotransmitter abnormalities, however, have been observed in this and other basal ganglia diseases. This chapter wi作者: Nomadic 時(shí)間: 2025-3-28 12:57 作者: 闡釋 時(shí)間: 2025-3-28 15:56
Worship Spaces: 1001–2000 Seatselladonna extracts as mildly effective remedies in PD. Since that time, there has been hardly a drug that has not been tried in patients suffering from this disorder. The list even includes such compounds as ferric sulfate, barium chloride, strychnine, pentylenetetrazol, and diverse thyroid and pyra作者: Yag-Capsulotomy 時(shí)間: 2025-3-28 20:48 作者: Latency 時(shí)間: 2025-3-29 02:16 作者: STANT 時(shí)間: 2025-3-29 04:42
Worship Spaces: 1001–2000 Seatsctive therapy has augmented the need, now that we are in an era of ever-expanding novel therapeutic agents, combined with recognition of a wider variety of deficits (such as dementia), and experience with problematic adverse reactions (such as fluctuations in response). Besides making reliable sensi作者: 怒目而視 時(shí)間: 2025-3-29 07:44 作者: 蠟燭 時(shí)間: 2025-3-29 14:48 作者: inchoate 時(shí)間: 2025-3-29 16:36
Kate J. Bowers,Shane D. Johnsondisability. Since its introduction in the 1960s, LD continues to impress clinician and patient alike with its almost metaphysical prowess at “awakening” paralyzed movement, unlocking rigidity, and stilling the “cruel restlessness” of shaking in parkinsonism (. 1983). The degree of improvement with L作者: Bumptious 時(shí)間: 2025-3-29 23:19 作者: impale 時(shí)間: 2025-3-30 02:56
Assessment of Aggressiveness of , on Wheats to inhibit monoamine oxidase (MAO), the major enzyme metabolizing it in human brain, in order to conserve the attenuated supply. . and . (1959) had previously shown that the MAO inhibitors, iproniazid and harmine, increase the dopamine content of rabbit brain. Harmine had, in fact, been used very 作者: 憲法沒有 時(shí)間: 2025-3-30 04:35 作者: 吝嗇性 時(shí)間: 2025-3-30 12:06
Benjamin Schwessinger,John P. Rathjentain this response and become more symptomatic. Increasing disability is usually accompanied by dyskinesias and diurnal fluctuations in performance, predominantly “wearing-off” phenomena (. and . 1977; 1976). Occasionally, patients exhibit abrupt random fluctuations: “on-off” phenomena.作者: Constituent 時(shí)間: 2025-3-30 16:21
Benjamin Schwessinger,John P. Rathjens an 8-.-aminoergoline and was synthesized by . and . (1968). It is a white slightly bitter tasting substance, which is reasonably stable at room temperature if not exposed to light. Lisuride hydrogen maleate is soluble in water or saline up to 1 mg/ml. Owing to its low effective dose, it is therefo作者: Hormones 時(shí)間: 2025-3-30 20:26 作者: preservative 時(shí)間: 2025-3-30 22:50
,Update on Bromocriptine in Parkinson’s Disease,tain this response and become more symptomatic. Increasing disability is usually accompanied by dyskinesias and diurnal fluctuations in performance, predominantly “wearing-off” phenomena (. and . 1977; 1976). Occasionally, patients exhibit abrupt random fluctuations: “on-off” phenomena.作者: 外向者 時(shí)間: 2025-3-31 01:29 作者: LINE 時(shí)間: 2025-3-31 08:43 作者: Liberate 時(shí)間: 2025-3-31 11:46 作者: FOIL 時(shí)間: 2025-3-31 15:58 作者: 轎車 時(shí)間: 2025-3-31 21:28 作者: 認(rèn)為 時(shí)間: 2025-3-31 21:59
,Pergolide in the Treatment of Parkinson’s Disease,Pergolide mesylate, a synthetic semiergoline, is a potent dopamine agonist which holds promise as a treatment for Parkinson’s disease. Its chemical name is (8 .)-8-[(methylthio)methyl]-6-propylergoline monomethanesulfonate; its empirical formula is C.H.N.O.S. (Fig. 1), and its molecular weight is 410.6.作者: conjunctivitis 時(shí)間: 2025-4-1 03:27
Neurophysiology of Basal Ganglia, deficits in the basal ganglia would suggest at first sight a role of this brain structure in motor control. However, an absence of movement can have many causes. When discussing movement-related neuronal processes it is helpful to distinguish between the initiation and the execution of movements (.作者: biosphere 時(shí)間: 2025-4-1 09:51 作者: 相互影響 時(shí)間: 2025-4-1 12:45
Biochemical Neuroanatomy of the Basal Ganglia,opic since the early days of biochemical neuroanatomy because many of the classical neurotransmitters are found in very high concentration in extrapyramidal nuclei, these nuclei are relatively distinct and easily dissected, and classical pathological studies had demonstrated a clear association betw作者: 失誤 時(shí)間: 2025-4-1 14:53
Receptors in the Basal Ganglia, the function of specific neuronal pathways in health and disease. In Parkinson’s disease, the emphasis has been on the study of dopamine presynaptic and postsynaptic elements. Other neurotransmitter abnormalities, however, have been observed in this and other basal ganglia diseases. This chapter wi作者: legacy 時(shí)間: 2025-4-1 20:12 作者: 蝕刻 時(shí)間: 2025-4-2 01:19 作者: tariff 時(shí)間: 2025-4-2 04:19
Pyridine Toxins,g on experimental models, would be flawed without a discussion of this newly discovered relationship. This striking turn of events has been precipitated almost entirely by the discovery of a single compound, l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine, or, as it is now widely know, MPTP. In this ch
